这两种药能有多大的效果？

闹心啊

Chimigen™ Hepatitis B Therapeutic Vaccines

Hepatitis B is one of the major diseases of mankind and is a serious global public health problem. The World Health Organization estimates that one out of every three people have been infected with the HBV of whom approximately 350 million have developed a chronic HBV infection.

ViRexx has a Chimigen™ Hepatitis B Therapeutic Vaccine candidate that has completed Phase I trials and two other candidates in preclinical development that have real potential to address the challenges involved in targeting chronic HBV infection.
PROGRAM STATUS: Preclinical-Phase I
ViRexx has completed a Phase I clinical trial for one of its Chimigen™ Hepatitis B Therapeutic Vaccine candidates (formerly called HepaVaxx B Vaccine) in 15 normal, healthy volunteers. There were no significant adverse events associated with the treatment.  The evaluation of the immune responses in these volunteers to the treatment with a single dose of the Chimigen™ Hepatitis B Therapeutic Vaccine revealed no significant humoral or cellular responses elicited by the vaccination.

ViRexx has identified a new Chimigen™ Hepatitis B virus therapeutic Vaccine Candidate, which includes multiple antigens shown to be involved in a therapeutic immune response in chronic hepatitis B patients.  ViRexx hopes to initiate a clinical trial for its Chimigen™ Hepatitis B Virus Therapeutic Vaccine with an Asian partner in the second half of 2009.

Partnering discussions have been initiated for Chimigen™ Hepatitis B Therapeutic Vaccine. Specifically, ViRexx is targeting potential partners with a strong presence in Asia and India where almost three quarters of the world’s chronic hepatitis B sufferers exist.
Hepatitis B (HBV) EHT899

Enzo is developing HBV therapeutics utilizing our immune regulation technology.
HBV is a viral pathogen that can lead to a condition in which the body destroys its own liver cells through an immune response.  This condition is commonly referred to as chronic active hepatitis.  According to the latest figures published by the World Health Organization, approximately 2 billion people are infected by HBV, in whom an estimated 350 million are chronically infected and therefore at risk of death from liver disease.

Chronic active hepatitis is generally treated with interferon or lamivudine.  Both of these drugs, however, are toxic, and many patients cannot tolerate their side effects.   These treatments have a limited success rate (5-15%).

Enzo’s EHT899 immune regulation product. EHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune response elicited by the HBV infection.  It also apparently enhances a secondary immune response to clear the viral infection, resulting in reduction in liver damage and decrease in viral load.

In a clinical trial, conducted at the Liver Unit of Hadassah-Hebrew University Medical Center, in Jerusalem, Israel, a formulation of EHT899 was administered orally to a total of 42 patients with chronic active hepatitis.   Patients received the medication three times a week for 20 – 30 weeks and were followed for an additional 20 weeks.  Results of the trial have shown that the drug was well tolerated in all subjects; 46% of subjects showed a decrease in HBV viral load and improvement in liver function tests; and 33% of subjects showed a decrease in inflammation seen on liver biopsy.
Based on these results, Enzo is preparing to begin a multi-center Phase II random-label double blind clinical study.

Preclinical animal studies with EHT899 showed that this medication was able to achieve complete suppression of HBV-associated human liver cancer and significantly reduced mortality in laboratory mice.  These studies may have significant potential application for treatment of liver and other cancers in humans.
以上资料来源于美国乙型肝炎基金会链接。
感觉仅仅是有效，离我们的愿望较远。

走遍四方

还有好长的路走

恍若隔世

饿看不懂